May 15th 2024
A large study on the future directions unveiling COVID-19 vaccine safety and risks.
Medical Crossfire®: Maximizing Patient Outcomes in Shingles – Are You Leveraging Guideline Based Care?
View More
Understanding RSV: What You Need to Know to Prevent and Treat Respiratory Syncytial Virus in Your Patients
View More
Respiratory Syncytial Virus: Understanding the Infection Burden and Anticipating the Impact of Vaccines
View More
(COPE Credit) Community Practice Connections™: Keeping an Eye on Evolving Management Strategies for nAMD and DME
View More
(CME Credit) Community Practice Connections™: Keeping an Eye on Evolving Management Strategies for nAMD and DME
View More
Medical Crossfire®: Which Patients with Hematologic Malignancies are at Risk for Secondary Immunodeficiency (SID)… and How Can We Leverage Evidence to Improve Their Outcomes?
View More
Addressing Healthcare Inequities™ in Glaucoma Management – Understanding Challenges in Segmented Patient Populations (CME Track)
View More
Myeloma Management Considerations: Applying the Evidence With Monoclonal Antibody Based Regimens
View More
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Tackling Inequities in IBD: Inclusive Solutions for Elevated Patient Care
October 26, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Patient, Provider, and Caregiver Connection™: Prevention and Control of Meningococcal Disease — Individualizing Vaccine Recommendations in Adolescent Populations
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Addressing Healthcare Inequities: Bridging the Gap in Multiple Sclerosis – A Focus on Clinical and Healthcare Disparities in Black Patients
View More
Overcoming Racial Disparities in Multiple Myeloma Outcomes and Clinical Trials: How We are Moving Care Forward Today
View More
Johnson & Johnson Report Promising COVID-19 Vaccine Booster Efficacy, Long-Term Data
September 21st 2021Preprint data from a real-world evidence assessment, as well as preliminary reports from a 2-dose trial, support the company's pursuit for FDA authorization of a second COVID-19 vaccine dose.
Read More
FDA Committee Votes to Recommend EUA of COVID-19 Booster Dose in Older, High-Risk People
September 17th 2021After voting against recommendation of a booster dose for people 16 years and older, the committee created a new question to vote on an EUA for a booster dose for people 65 years and older and those at high risk of COVID-19. They voted 18-0 in favor.
Read More
FDA Meeting Today to Discuss Booster Doses
September 17th 2021A Food and Drug Administration (FDA) committee will discuss this topic as it pertains to the potential approval of a third dose of the Pfizer-BioNTech COVID-19 vaccine. The results of this meeting could have ramifications for the Biden Administration’s COVID-19 health policy.
Read More
Maternity Mortality Increase During COVID-19 Affirms Value of Vaccination During Pregnancy
September 14th 2021A study from Mexico shows that maternal mortality increased nearly 60 percent during the COVID-19 pandemic, and reaffirms the importance of both COVID-19 and influenza vaccinations for pregnant women.
Watch
Review Panel: Scientific Evidence Does Not Support Booster Doses
September 13th 2021Even with the Delta variant as the predominant strain now, a group scientists concluded that vaccine efficacy against severe COVID-19 is so high that booster doses for the general population are not appropriate at this stage in the pandemic.
Read More
CDC: Vaccinated People Reduce Risk of COVID-19 Mortality by More Than 10 Times
September 10th 2021In a large study looking at incidence rates for hospitalization and mortality, results changed relatively little in terms of vaccine effectiveness, even after the Delta variant became the dominant strain.
Read More